Clinical trial
Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent…
NCT00305461 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00305461 |
|---|---|
| Title | Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101) |
| Official title | A Pilot Study on the Impact of Two Different Doses of Ciclesonide (160 mcg/Day and 320 mcg/Day) Administered in the Evening on Quality of Life in Patients With Moderate Persistent Asthma. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Ciclesonide |
| Enrollment | 101 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Mar 22, 2006 |
| Last update posted | Dec 5, 2016 |
| Countries | Argentina |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: